Golden Age Health

Golden Age Health (GAH) is a specialty pharmaceutical platform focused on bridging the gap between innovative global therapies and patients in China, Asia-Pacific, and the Middle East. Founded by a veteran leadership team including Executive Chairman Michel Vounatsos (former CEO of Biogen), the company operates an end-to-end commercialization model that covers regulatory strategy, market access, and real-world evidence generation. Its current portfolio includes ZTALMY (ganaxolone), the first approved treatment for CDKL5 deficiency disorder in China, and LX-101, a late-stage gene therapy for RPE65-related inherited retinal dystrophies. GAH serves as a strategic partner for global biotechs looking to navigate complex regional landscapes and accelerate the delivery of life-changing treatments to underserved populations.